A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...
The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery ...
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...